BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Summary by AI BETAClose X

BioNTech will present new clinical data and trial updates from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting, highlighting pumitamig's encouraging anti-tumor activity in first-line non-small cell lung cancer and gotistobart's potential as a chemotherapy-free treatment option for platinum-resistant ovarian cancer, with over 25 Phase 2 and Phase 3 trials, including 13 pivotal trials, advancing across major cancer types.

Disclaimer*

UK 100

Latest directors dealings